1. A novel methylated cell-free DNA marker panel to monitor treatment response in metastatic prostate cancer
- Author
-
Madonna R Peter, Misha Bilenky, Yuliang Shi, Jiajie Pu, Shivani Kamdar, Aaron R Hansen, Neil E Fleshner, Srikala S Sridhar, Anthony M Joshua, Martin Hirst, Wei Xu, and Bharati Bapat
- Subjects
Male ,Cancer Research ,Prostatic Neoplasms, Castration-Resistant ,Genetics ,Androgens ,Biomarkers, Tumor ,Humans ,DNA ,Cell-Free Nucleic Acids - Abstract
Aim: This study examined circulating cell-free DNA (cfDNA) biomarkers associated with androgen treatment resistance in metastatic castration resistance prostate cancer (mCRPC). Materials & methods: We designed a panel of nine candidate cfDNA methylation markers using droplet digital PCR (Methyl-ddPCR) and assessed methylation levels in sequentially collected cfDNA samples from patients with mCRPC. Results: Increased cfDNA methylation in eight out of nine markers during androgen-targeted treatment correlated with a faster time to clinical progression. Cox proportional hazards modeling and logistic regression analysis further confirmed that higher cfDNA methylation during treatment was significantly associated with clinical progression. Conclusion: Overall, our findings have revealed a novel methylated cfDNA marker panel that could aid in the clinical management of metastatic prostate cancer.
- Published
- 2022